Alan Warrander
Keine laufenden Positionen mehr
Profil
Alan Warrander served as a Non-Executive Director at Incanthera Research & Development Ltd.
and as an Independent Non-Executive Director at Incanthera Plc from 2017 to 2022.
He was also the SVP-Global Licensing & Business Development at Oncolytics Biotech, Inc. from 2009 to 2011 and a Research Analyst at Objective Capital Ltd.
Dr. Warrander holds a doctorate from the University of Birmingham and an undergraduate degree from the University of St. Andrews.
Ehemalige bekannte Positionen von Alan Warrander
| Unternehmen | Position | Ende |
|---|---|---|
Incanthera Plc
 Incanthera Plc Pharmaceuticals: MajorHealth Technology Incanthera Plc operates as a holding company, which focuses on drug discovery and development of targeted medicines for the treatment of cancer. The firm products include Sol, EP0015, Equin & Duo-C. The company was founded on March 2, 2010 and is headquartered in Manchester, the United Kingdom. | Direktor/Vorstandsmitglied | 28.02.2022 |
Objective Capital Ltd.
 Objective Capital Ltd. Investment Banks/BrokersFinance Objective Capital Ltd. provides investment research. The company is based in London, UK. The British company was founded by Gabriel Didham. | Analyst-Equity | - |
Incanthera Research & Development Ltd.
 Incanthera Research & Development Ltd. Medical DistributorsDistribution Services Incanthera Research & Development Ltd. develops drug delivery solutions for solid tumor chemotherapy. It offers cancer therapies, such as ICT01-2588, a vascular disrupting agent and drug delivery platform for lung and prostate cancer; and ICT03-Es5, a bioreductive anticancer agent for lung, liver, and breast cancer. The company was founded by Alan McGowan, Paul Loadman, Laurence Patterson, Andrew John Michael Duley, John Anthony Hadfield, Robert Falconer, and Jason Gill in 2010 and is headquartered in Manchester, the United Kingdom. | Direktor/Vorstandsmitglied | - |
| ONCOLYTICS BIOTECH INC. | Corporate Officer/Principal | - |
Ausbildung von Alan Warrander
| University of Birmingham | Doctorate Degree |
| University of St. Andrews | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ONCOLYTICS BIOTECH INC. | Health Technology |
 | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Objective Capital Ltd.
Objective Capital Ltd. Investment Banks/BrokersFinance Objective Capital Ltd. provides investment research. The company is based in London, UK. The British company was founded by Gabriel Didham. | Finance |
Incanthera Research & Development Ltd.
Incanthera Research & Development Ltd. Medical DistributorsDistribution Services Incanthera Research & Development Ltd. develops drug delivery solutions for solid tumor chemotherapy. It offers cancer therapies, such as ICT01-2588, a vascular disrupting agent and drug delivery platform for lung and prostate cancer; and ICT03-Es5, a bioreductive anticancer agent for lung, liver, and breast cancer. The company was founded by Alan McGowan, Paul Loadman, Laurence Patterson, Andrew John Michael Duley, John Anthony Hadfield, Robert Falconer, and Jason Gill in 2010 and is headquartered in Manchester, the United Kingdom. | Distribution Services |
